Based on the DCF valuation, Fosun Hanibelieves the reasonable market value is RMB 32.6 billion, corresponding to HK$230 per share. Based on the valuation of the number of cases per unit, Fosun Hanibelieves that the reasonable market value is RMB 31.8 billion, corresponding to HK$224 per share. Combining the two valuation methods, our target price is HK$224, which still has upside potential from the current price.